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	 Background In addition to genomic signalling, oestrogen receptor α (ERα) is associated with cell proliferation and 
survival through a nongenomic (extranuclear) signalling pathway, which is considered to contribute to endocrine 
resistance. However, the relationship between extranuclear ERα expression levels and endocrine therapy (ET) resistance 
has not been studied extensively. My goal was to assess ERα expression levels in the cytoplasm and/or at the membrane 
in breast cancer specimens using IHC with PIDs (IHC-PIDs) as a retrospective research tool and to explore the 
significance of extranuclear ERα in predicting the benefit of ET and patient prognosis. Methods ERα expression levels 
were quantified in cells lines and tissue section with a range of increasing ERα expression by using IHC-PIDs, flow 
cytometry and real-time quantitative reverse transcription-PCR (real-time qRT-PCR). GFP-ERαΔNLS-transfected cells 
were stained with PIDs to detect extranuclear ERα. Then, sixty-five patients with HR+/HER2- breast cancer from 2001 
to 2003 who were treated with postoperative ET were selected. Tissue sections were stained with IHC-PIDs, and total 
ERα, nuclear ERα, extranuclear ERα, and the ratio of extranuclear-to-nuclear ERα (ENR) were then measured with an 
automatic computerized measurement named “the nearest-neighbour method”. The correlations among biological factors, 
clinical characteristics and pathological features were examined. Results PIDs were able to specifically quantify ERα as 
the results of strong correlation between PIDs score and mRNA expression (Pearson r2=0.94) as well as FACS (Pearson 
r2=0.98). PIDs exhibit appropriate recognition of extranuclear ER in cancer cells. 4 µm was chosen as the optimal value 
for the nearest-neighbor method which provides an accurate measurement of the extranuclear ERα protein expression 
level. The PIDs scores of total and nuclear ERα negatively correlated with relapse, and the ERα ENR calculated by the 
nearest-neighbour method was positively correlated with relapse. A high (≥48) nuclear ERα PIDs score was associated 
with better disease-free survival (DFS) (log-rank P=0.022). However, a high (≥0.5) ERα ENR was significantly 
associated with poor OS (log-rank P=0.048) and DFS (log-rank P=0.007). Multivariate analysis revealed that the ERα 
ENR remained an independent prognostic factor for DFS [hazard ratio, 3.8; 95% CI, 1.4~11.8; P=0.006]. Conclusion I 
used IHC-PIDs imaging to develop a novel automatic computerized measurement with high accuracy for localizing and 
assessing extranuclear ERα, which was previously rarely detected. I demonstrated a new method for localizing and 
assessing extranuclear protein that can be applied to other biomarkers to explore their underlying mechanisms. A high 
ERα ENR and/or low nuclear ERα PIDs score in HR+/HER2- breast cancer indicates a decreased chance of benefitting 
from ET. 
